ArticleWorld journal of gastroenterology2018
Biomarkers for hepatocellular carcinoma: What's new on the horizon?
Article in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Pooled it
- Coaxial liver biopsy with tract electrocauterization: technique and outcomes in high-risk patients with suspected hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- Evaluating the role of preoperative serum insulin-like growth factor 1 as a predictor of survival and recurrence for patients with resectable hepatocellular carcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2026Article
- Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma.Therapeutic advances in medical oncology · 2025Review
- Enhancement of treatment efficacy of hepatic tumours using Trans-arterial-chemoembolization.American journal of cancer research · 2023Review
- ELL associated factor 2 is a potential diagnostic and prognostic indicator: evidence from the in silico and in vitro experiments.American journal of cancer research · 2023Article
- Identifying Potential Tumor Antigens and Antigens-Related Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development.Journal of oncology · 2022Article
- Identification of senescence-associated long non-coding RNAs to predict prognosis and immune microenvironment in patients with hepatocellular carcinoma.Frontiers in genetics · 2022Article
- Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.Frontiers in oncology · 2022Article
- Novel Molecular Targets for Hepatocellular Carcinoma.Cancers · 2021Article
- Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma.Hepatic oncology · 2021Article
- Article
- Serum Golgi protein 73 as a sensitive biomarker for early detection of hepatocellular carcinoma among Egyptian patients with hepatitis C virus-related cirrhosis.Medical journal, Armed Forces India · 2021Article
- Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma.Scientific reports · 2021Article
- Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development.Clinical and experimental hepatology · 2021Article
- Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma.Frontiers in oncology · 2021Review
- Dissecting the immune cell landscape in hepatocellular carcinoma-are we understanding complexity?Annals of translational medicine · 2020Article
- Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation.Vaccines · 2020Review
- Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma.International journal of general medicine · 2020Article
- CancerLivER: a database of liver cancer gene expression resources and biomarkers.Database : the journal of biological databases and curation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of advanced hepatocellular carcinoma remains unsatisfying and so far only prognostic biomarkers like α-fetoprotein have been established. No clear predictive biomarker is currently available for standard of care therapies, including targeted therapies like sorafenib. Novel therapeutic options like immune checkpoint inhibitors may pose new challenges to identification and validation of such markers. Currently, PD-L1 expression
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.